{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:42:47Z","timestamp":1790934167970,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the NIH Intramural Research Program (IRP) of the National Institute on Drug Abuse and the National Institute of Alcohol Abuse and Alcoholism","award":["Z1A DA000606\u2014L.S."],"award-info":[{"award-number":["Z1A DA000606\u2014L.S."]}]},{"name":"the NIH Intramural Research Program (IRP) of the National Institute on Drug Abuse","award":["Z1A DA000606\u2014L.S."],"award-info":[{"award-number":["Z1A DA000606\u2014L.S."]}]},{"name":"The X-ray crystallographic work was supported by NIDA through an Interagency Agreement #Y1-DA1101 with the Naval Research Laboratory","award":["Z1A DA000606\u2014L.S."],"award-info":[{"award-number":["Z1A DA000606\u2014L.S."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Four sets of diastereomeric C9-alkenyl 5-phenylmorphans, varying in the length of the C9-alkenyl chain, were designed to examine the effect of these spatially distinct ligands on opioid receptors. Functional activity was obtained by forskolin-induced cAMP accumulation assays and several compounds were examined in the [35S]GTPgS assay and in an assay for respiratory depression. In each of the four sets, similarities and differences were observed dependent on the length of their C9-alkenyl chain and, most importantly, their stereochemistry. Three MOR antagonists were found to be as or more potent than naltrexone and, unlike naltrexone, none had MOR, KOR, or DOR agonist activity. Several potent MOR full agonists were obtained, and, of particular interest partial agonists were found that exhibited less respiratory depression than that caused by morphine. The effect of stereochemistry and the length of the C9-alkenyl chain was also explored using molecular modeling. The MOR antagonists were found to interact with the inactive (4DKL) MOR crystal structures and agonists were found to interact with the active (6DDF) MOR crystal structures. The comparison of their binding modes at the mouse MOR was used to gain insight into the structural basis for their stereochemically induced pharmacological differences.<\/jats:p>","DOI":"10.3390\/molecules27196455","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T04:00:02Z","timestamp":1665288002000},"page":"6455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists"],"prefix":"10.3390","volume":"27","author":[{"given":"Dana R.","family":"Chambers","sequence":"first","affiliation":[{"name":"Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Sulima","sequence":"additional","affiliation":[{"name":"Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0649-8052","authenticated-orcid":false,"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, 333 Cassell Drive, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-7199","authenticated-orcid":false,"given":"Bing","family":"Xie","sequence":"additional","affiliation":[{"name":"Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, 333 Cassell Drive, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[{"name":"Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, 333 Cassell Drive, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Paronis","sequence":"additional","affiliation":[{"name":"McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Bergman","sequence":"additional","affiliation":[{"name":"McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Nassehi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana E.","family":"Selley","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory H.","family":"Imler","sequence":"additional","affiliation":[{"name":"Naval Research Laboratory, Center for Biomolecular Science and Engineering, Washington, DC 20375, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-8354","authenticated-orcid":false,"given":"Arthur E.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenner C.","family":"Rice","sequence":"additional","affiliation":[{"name":"Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","unstructured":"Small, L.F., and Lutz, R.E. (1932). Chemistry of the Opium Alkaloids, United States Government Printing Office. Volume Supplement 103 to the Public Health Reports."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.181.4098.407","article-title":"The Search for a Better Analgesic","volume":"181","author":"Eddy","year":"1973","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0376-8716(89)90083-5","article-title":"The Committee on Problems of Drug Dependence: A legacy of the National Academy of Sciences. A historical account","volume":"23","author":"May","year":"1989","journal-title":"Drug. Alcohol. Depend."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1021\/jo01126a008","article-title":"Structures Related to Morphine. IV. m-Substituted Phenylcyclohexane Derivatives","volume":"20","author":"May","year":"1955","journal-title":"J. Org. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel \u03bc-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108439","DOI":"10.1016\/j.neuropharm.2020.108439","article-title":"Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain","volume":"185","author":"Pantouli","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: A Novel Potent Analgesic Nociceptin\/Orphanin FQ Peptide and Opioid Receptor Agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1021\/acs.biochem.1c00466","article-title":"Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists","volume":"61","author":"Stahl","year":"2021","journal-title":"Biochemistry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/mol.119.119214","article-title":"Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window","volume":"98","author":"Gillis","year":"2020","journal-title":"Molec. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2102178118","DOI":"10.1073\/pnas.2102178118","article-title":"G protein signaling\u2013biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists","volume":"118","author":"Stahl","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1039\/D0MD00104J","article-title":"G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9","volume":"11","author":"Gutman","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.199942","article-title":"Stereospecific and Nonstereospecific Effects of (+)- and (\u2212)- Morphine: Evidence for a New Class of Receptors?","volume":"198","author":"Jacquet","year":"1977","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1021\/jm061325e","article-title":"Probes for Narcotic Receptor Mediated Phenomena. 34. Synthesis and Structure-Activity Relationships of a Potent \u03bc-Agonist \u03b4-Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric C9-Substituted 5-(3-Hydroxyphenyl)-N-phenylethylmorphan Series","volume":"50","author":"Hiebel","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1016\/S0040-4039(99)00566-3","article-title":"An expedient synthesis of 9-keto-2-methyl-5-(dimethoxyphenyl)morphans","volume":"40","author":"Linders","year":"1999","journal-title":"Tetrahedron Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100390","DOI":"10.1016\/j.rechem.2022.100390","article-title":"Optimized synthesis of enantiomeric C9-keto-5-phenylmorphans, essential intermediates for novel MOR agonists and antagonists","volume":"4","author":"Sulima","year":"2022","journal-title":"Results Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12929-021-00758-y","article-title":"Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent","volume":"28","author":"Hedrick","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/1087057111406548","article-title":"Understanding the Effect of Different Assay Formats on Agonist Parameters: A Study Using the \u00b5-Opioid Receptor","volume":"16","author":"Nickolls","year":"2011","journal-title":"SLAS Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eaaz3140","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"[19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors","volume":"Volume 25","author":"Sealfon","year":"1995","journal-title":"Methods in Neurosciences"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the \u00b5-opioid receptor-G(i) protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the \u03bc-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"18684","DOI":"10.1073\/pnas.1110499108","article-title":"Activation mechanism of the \u03b22-adrenergic receptor","volume":"108","author":"Dror","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jpain.2018.02.003","article-title":"Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys","volume":"19","author":"Withey","year":"2018","journal-title":"J. Pain"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, M., Irvin, T.C., Herdman, C.A., Hanna, R.D., Hassan, S.A., Lee, Y.-S., Kaska, S., Crowley, R.S., Prisinzano, T.E., and Withey, S.L. (2020). The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of \u201cTail Wags Dog\u201d Experiments. Molecules, 25.","DOI":"10.3390\/molecules25112640"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/jm801272c","article-title":"Design, Synthesis, and Biological Evaluation of 6\u03b1- and 6\u03b2-N-Heterocyclic Substituted Naltrexamine Derivatives as \u03bc Opioid Receptor Selective Antagonists","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/jpet.120.000349","article-title":"Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids","volume":"376","author":"Selley","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acschemneuro.0c00191","article-title":"Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Design, Synthesis, and Evaluation of Analogues with Improved Potency and G-protein Activation Bias at the \u03bc-Opioid Receptor","volume":"11","author":"Crowley","year":"2020","journal-title":"ACS Chem. Neurosci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/19\/6455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:33Z","timestamp":1760143473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/19\/6455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":28,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["molecules27196455"],"URL":"https:\/\/doi.org\/10.3390\/molecules27196455","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}